Glial cell line?derived neurotrophic factor in brain repair after focal ischemic stroke
Zhe Zhang1
Nannan Zhang2
Shinghua Ding1
1.Department of Biomedical,Biological and Chemical Engineering,University of Missouri-Columbia,MO,USA;Dalton Cardiovascular Research Center,University of Missouri-Columbia,MO,USA2.Dalton Cardiovascular Research Center,University of Missouri-Columbia,MO,USA
摘要：Cerebral focal ischemic stroke (FIS) is a leading brain disorder associated with human debilitation and death. It is induced by the formation of a thrombus in the arteries that supply blood to the central nervous system. FIS patients may suddenly experience paralysis, impairment of speech and loss of vision. Most patients develop permanent disabilities. In the past decades, enormous efforts have been taken to develop FIS treatment strategies, but unfortunately, there is still a lack of effective ones for this disease. Currently, tissue plasminogen activator is the only Food and Drug Administration approved drug for FIS treatment, however, this method has limited application since it is only effective within 3–5 hours after the onset of FIS. Because of this, the recovery from FIS largely depends on self-brain repair and rehabilitation (Campbell et al., 2019).
机标关键词：
论文发表日期：2022-08-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1735-1736 )